Replacement of (R)-methadone by a double dose of (R,S)- methadone in addicts: Interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics

European Journal of Clinical Pharmacology

Volumn 50, Issue 5, 1996, Pages 385-389

  Eap, C B ^a   Finkbeiner, T ^b   Gastpar, M ^b   Scherbaum, N ^b   Powell, K ^a   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b Klin F Allgemeine Psychiatrie   (Germany)

Author keywords

Enantiomer; Induction; Metabolism; Methadone; Opioid addicts

Indexed keywords

METHADONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DEPENDENCE TREATMENT; DRUG DISPOSITION; DRUG METABOLISM; ENANTIOMER; HUMAN; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RACEMIC MIXTURE;

ADULT; ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; METHADONE; STEREOISOMERISM; SUBSTANCE-RELATED DISORDERS;

EID: 0029941892     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050128     Document Type: Article

References (27)

1. Pert CB, Snyder SH (1973) Opiate receptor: demonstration in nervous tissue. Science 179: 1011-1014
2. Scott CC, Robbins EB, Chen KK (1948) Pharmacological comparison of the optical isomers of methadone. J Pharmacol Exp Ther 92: 282-286
3. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N (1977) Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 21: 147-157
4. Fraser HF, Isbell H (1962) Human pharmacology and addictiveness of certain dextroisomers of synthetic analgesics: I. d-3-hydroxy-N-phenethylmorphinan. II. d-3-methoxy-N-phenethylmorphinan. III. d-methadone. Bull Narc XIV: 25-35
5. Verebely K, Volavka J, Mulé S, Resnick R (1975) Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 18: 180-190
6. Nilsson M-I, Anggard E, Holmstrand J, Gunne L-M (1982) Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol 22: 343-349
7. Änggard E, Gunne L-M, Holmstrand J, McMahon RE, Sandberg C-G, Sullivan HR (1975) Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 17: 258-266
8. Spaulding T, Minium L, Kotake AN, Takemori AE (1974) The effect of diazepam on the metabolism of methadone by the liver of methadone-dependent rats. Drug Metab Dispos 2: 458-463
9. Bertschy G, Baumann P, Eap CB, Baettig D (1994) Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 16: 42 45
10. Kreek MJ, Hachey DL, Klein PD (1995) Stereoselective disposition of methadone in man. Life Sci 24: 925-932
11. 8)methadone. J Pharm Sci 71: 40-43
12. Schmidt N, Brune K, Williams KM, Geisslinger G (1994) Stereoselective pharmacokinetics of methadone in beagle dogs. Chirality 6: 492 495
13. Beck O, Boreus LO, Lafolie P, Jacobsson G (1991) Chiral analysis of methadone in plasma by high-performance liquid chromatography. J Chromatogr Biomed Appl 570: 198-202
14. Schmidt N, Brune K, Geisslinger G (1992) Stereoselective determination of the enantiomers of methadone in plasma using high-performance liquid chromatography. J Chromatogr Biomed Appl 583: 195-200
15. Kristensen K, Angelo HR (1992) Stereospecific gas Chromatographic method for determination of methadone in serum. Chirality 4: 263-267
16. Holmstrand J, Änggard E, Gunne L-M (1978) Methadone maintenance: plasma levels and therapeutic outcome. Clin Pharmacol Ther 23: 175-180
17. Loimer N, Schmid R (1992) The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend 30: 241-246
18. Wolff K, Hay AWM, Raistrick D (1992) Plasma methadone measurements and their role in methadone detoxification programmes. Clin Chem 38: 420-425
19. Horns WH, Rado M, Goldstein A (1975) Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther 17: 636-649
20. Bell J, Bowron P, Lewis J, Batey R (1990) Serum levels of methadone in maintenance clients who persist in illicit drug use. Br J Addict 85: 1599-1602
21. Borg L, Kreek MJ (1995) Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1-positive and AIDS patients. Curr Opin Psychiatr 8:199-202
22. Sullivan HR, Due SL (1973) Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 16: 909-913
23. Coutts RT, Su P, Baker GB (1994) Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 31: 177-186
24. Yue QY, Svensson JO, Bertilsson L, Säwe J (1995) Racemic methadone kinetics in relation to the debrisoquine hydroxylation polymorphism in man. Therapie (Abstracts of the 1st Congress of the European Association for Clinical Pharmacology and Therapeutics. September 27-30, 1995, Paris, France). Abstract No. 88
25. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
26. Kalow Wand Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49: 44-48
27. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22: 49 53